BariL, BacsaS, SonkolyEet al.Comparison of stress-induced PRINS gene expression in normal human keratinocytes and HaCaT cells. Arch Dermatol Res, 2011; 303:745–752.
2.
MontesuM, AddisG, SattaR, CottoniF. Adverse reactions during biological drug therapy in psoriasis: Clinical series and a review of the literature. G Ital Dermatol Venereol, 2011; 146:273–281.
3.
WetzelA, WetzigT, HausteinUFet al.Increased neutrophil adherence in psoriasis: Role of the human endothelial cell receptor Thy-1 (CD90)J Invest Dermatol, 2006; 126:441–452.
4.
AvramidisG, Krüger-KrasagakisS, KrasagakisKet al.The role of endothelial cell apoptosis in the effect of etanercept in psoriasis. Br J Dermatol, 2010; 163:928–934.
5.
BalatoA, LemboS, CirilloT, MegnaMet al.Anti-tumor necrosis factor-α therapy in the management of psoriasis and B-chronic lymphocytic leukemia. Case Rep Dermatol, 2011; 3:60–63.
6.
MakinoS, MitsutakeN, NakashimaMet al.DHMEQ, a novel NF-kappaB inhibitor, suppresses growth and type I collagen accumulation in keloid fibroblasts. J Dermatol Sci, 2008; 51:171–180.
7.
ZhouQ, MrowietzU, Rostami-YazdiM. Oxidative stress in the pathogenesis of psoriasis. Free Radic Biol Med, 2009; 47:891–905.
8.
GrossmanRM, KruegerJ, YourishDet al.Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci U S A, 1989; 86:6367–6371.
9.
MussiA, BonifatiC, CarducciMet al.IL-10 levels are decreased in psoriatic lesional skin as compared to the psoriatic lesion-free and normal skin suction blister fluids. J Biol Regul Homeost Agents, 1994; 8:117–120.
10.
HuskićJ, MulabegovićN, AlendarFet al.Serum and tissue angiotensin converting enzyme in patients with psoriasis. Coll Antropol, 2008; 32:1215–1219.
11.
HuskićJ, AlendarF. Tissue angiotensin-converting enzyme in patients with various clinical forms of psoriasis. Bosn J Basic Med Sci, 2007; 7:103–106.
12.
Sikar AktürkA, OzdoğanHK, BayramgürlerDet al.Nitric oxide and malondialdehyde levels in plasma and tissue of psoriasis patients. J Eur Acad Dermatol Venereol, 2011July13e-pub ahead of print.
13.
JinT, ChenYW, HowardA, ZhangYZ. Purification, crystallization and initial crystallographic characterization of the Ginkgo biloba 11S seed globulin ginnacin. Acta Crystallogr Sect F Struct Biol Cryst Commun, 2008; 64:641–644.
14.
FeiR, FeiY, ZhengSet al.Purified polysaccharide from Ginkgo biloba leaves inhibits P-selectin-mediated leucocyte adhesion and inflammation. Acta Pharmacol Sin, 2008; 29:499–506.
15.
IlievaI, OhgamiK, ShiratoriKet al.The effects of Ginkgo biloba extract on lipopolysaccharide-induced inflammation in vitro and in vivo. Exp Eye Res, 2004; 79:181–187.
16.
LiGH, LeiXX, YiYMet al.Studies on the effect of Ginkgo biloba extracts on NF-kappaB pathway [in Chinese]Zhong Yao Cai, 2008; 31:1357–1360.
17.
HeM, ZhangXM, YuanHQ. Clinical study on treatment of pulmonary interstitial fibrosis with ginkgo extract. Zhongguo Zhong Xi Yi Jie He Za Zhi, 2005; 25:222–224.
18.
JiaoYB, RuiYC, YangPYet al.Effects of Ginkgo biloba extract on expressions of IL-1beta, TNF-alpha, and IL-10 in U937 foam cells. Yao Xue Xue Bao, 2007; 42:930–934.
19.
MansourSM, BahgatAK, El-KhatibAS, KhayyalMT. Ginkgo biloba extract (EGb 761) normalizes hypertension in 2K, 1C hypertensive rats: Role of antioxidant mechanisms, ACE inhibiting activity and improvement of endothelial dysfunction. Phytomedicine, 2011; 18:641–647.
20.
YangTH, YoungYH, LiuSH. EGb 761 (Ginkgo biloba) protects cochlear hair cells against ototoxicity induced by gentamicin via reducing reactive oxygen species and nitric oxide-related apoptosis. J Nutr Biochem, 2011; 22:886–894.
